Limiting the Duration of Medication Assisted Treatment for Opioid Addiction: Will New State Policies Help or Hurt? by Clark, Robin E. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Commonwealth Medicine Publications Commonwealth Medicine 
2014-06-25 
Limiting the Duration of Medication Assisted Treatment for Opioid 
Addiction: Will New State Policies Help or Hurt? 
Robin E. Clark 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/commed_pubs 
 Part of the Health Economics Commons, Health Law and Policy Commons, Health Policy Commons, 
Health Services Administration Commons, Health Services Research Commons, and the Substance 
Abuse and Addiction Commons 
Repository Citation 
Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH. (2014). Limiting the Duration of 
Medication Assisted Treatment for Opioid Addiction: Will New State Policies Help or Hurt?. 
Commonwealth Medicine Publications. https://doi.org/10.13028/fn5e-vj16. Retrieved from 
https://escholarship.umassmed.edu/commed_pubs/98 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Commonwealth 
Medicine Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Limiting the Duration of Medication 
Assisted Treatment for Opioid 
Addiction: Will New State Policies 
Help or Hurt? 
Supported by National Institute of Drug Abuse grant 
number  R01DA029741  
Medicaid Evidence-Based Decisions Project 
June 25, 2014 
The UMass Research Team 
• Robin Clark, PhD 
• Jeff Baxter, MD 
• Bruce Barton, PhD 
• Gideon Aweh, MS 
• Elizabeth O’Connell, 
MS 
• Bill Fisher, PhD 
This presentation is solely the responsibility of the authors and  
does not necessarily represent the views of the Massachusetts 
EOHHS or of NIDA.  The authors have no conflicts of interest to 
disclose. 
Treatment for Opioid Dependence 
• A variety of drug-free treatments, 
including professionally led and self-
help 
• Medication assisted treatment 
–Buprenorphine   
–Methadone 
–Naltrexone 
Evidence strongly supports 
medication assisted treatment 
• Effectiveness of drug free treatment 
varies widely 
• Methadone is slightly more effective 
than buprenorphine 
• Extended release naltrexone not 
available until late 2010 
Concerns about medication 
assisted treatment (MAT) 
• Diversion 
• Methadone overdose 
• Cost of long-term maintenance 
• Public opinion (e.g. “substituting 
one opioid for another”) 
These concerns shape treatment 
access for Medicaid beneficiaries 
• Methadone maintenance is limited in 
many states 
• Increasingly, Medicaid programs are 
limiting the lifetime duration of treatment 
(6 months to 3 years) 
The state policy perspective 
1. How many long-term MAT users are 
there? 
2. What might the effects of restricted 
MAT treatment length be? 
3. Are non-drug treatments for opioid 
addiction a viable alternative? 
4. Can states save money by limiting the 
duration of treatment? 
Sample 
• 56,278 Medicaid members in MA treated 
for opioid addiction (2004 – 2010) 
• 108,145 episodes of treatment lasting 3 
months or more 
• Allowing for a break of up to 60 days 
within an episode 
Data 
• Medicaid claims and enrollment 2003 - 
2010 
• Merged with other Public Health 
treatment data 
• Relapse event = detoxification, 
emergency department visit, or 
hospitalization for substance abuse 
Study design 
• Compare buprenorphine, methadone 
and non-medication treatment episodes 
• Outcome measures: episode length, 
relapses per month, Medicaid 
expenditures per month 
• Adjust for demographics and clinical 
characteristics 
• Members followed for up to 36 months 
 
Type of Treatment Received1 
 
Characteristic 
Total 
(N =56,278) 
Buprenorphine 
(N = 18,866) 
Methadone 
(N = 24,309) 
Other 
(N =31,220) 
Gender, n (%) 
Male 32,636 (58.0) 10,999 (58.3) 14,089       (58.0) 17,274 (55.3) 
Female 23,642 (42.0) 7,867 (41.7) 10,220 (42.0) 13,946 (44.7) 
Average age2, mean (SD)  33.8 (10.4) 32.1 (9.5) 32.7 (9.8) 34.5 (10.7) 
CDPS2, mean (SD) 3.2 (2.0) 3.0 (1.7) 2.8 (1.8) 3.4 (2.2) 
Behavioral health  diagnosis2, n (%)  
SMI  13627 (24.2.9) 3,878 (20.6) 3,877 (16.0) 10,311 (33.0) 
Other 13,647 (24.3) 5,080 (26.9) 5,397 (22.2) 7,660 (24.5) 
Major depression 8,113 (14.5) 2,564 (13.6) 2,982 (12.3)    5,397 (17.3) 
Co-occurring substance use2, n (%)   
Alcohol 12,861 (22.9) 3,338 (17.7) 3,030 (12.5) 10,019 (32.1) 
Other drug  19,266 (34.2) 7,783 (41.3) 7,111 (29.3) 11,157 (35.7) 
Treatment episodes per person, mean 
(SD) 
1.9 (1.2) 1.3 (0.7) 1.3 (0.7) 1.5 (0.8) 
Medicaid expenditures3, mean (SD) $1,086 (2224) $867 (1802) $1,002 (1855) $1,485 (3074) 
Relapse during treatment4, n (%) 19,578 (34.8) 3,901 (20.7) 4,786 (19.7) 13,578 (43.7) 
MassHealth Members Treated for Opioid Addiction between 2004 -2010 
Length of Episodes: Methadone, 
Buprenorphine & Other Treatment 
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Percentage in treatment 
Treatment 
length 
Buprenorphine Methadone Other 
Month 1 100% 100% 100% 
Month 6 62% 78% 40% 
Month 12 33% 52% 12% 
Month 24 13% 27% 1% 
Month 36 5% 9% < 1% 
Statistical comparisons 
• Cox proportional hazards for time to 1st 
relapse 
• GEE for expenditures 
• Adjusted for age, gender, mental health 
diagnoses, other substance abuse, 
disease burden, relapses prior to the 
current episode, prior costs 
Relapse Rates: Methadone, 
Buprenorphine & Other Treatment 
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Factors contributing to relapse  
Full model includes: age, gender, disease burden, relapses 6 mos. before tx., severe 
mental illness, major depression, other mental illness, alcohol abuse, other drug 
abuse, treatment type. 
Cox proportional hazards survival model 
Factor Hazard rate 
Alcohol abuse  3.7 
Other drug abuse  2.1 
Relapses 6 months before treatment  1.9 
Severe mental illness 1.8 
Buprenorphine treatment 0.31 
Methadone treatment 0.26 
Average Monthly Medicaid 
Expenditures 
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Adjusted Monthly Costs —
selected factors1 
 Factor Regression coefficient (CI) 
Alcohol abuse $396   (360, 430) 
Severe mental illness $249   (220, 277) 
Other drug abuse $106    ( 86,125) 
Disease burden (per CDPS point) 2 $146   (135, 158) 
Buprenorphine treatment - $386 (- 409,- 363) 
Methadone treatment - $146 (- 170,-123) 
1 Full GEE model includes: age, gender, disease burden, cost before tx, severe mental illness, major 
depression, other mental illness, alcohol abuse, other drug abuse, treatment type. Clustered by year of 
treatment start. 
2 Chronic Illness and Disability Payment System.  Kronick et al 2000 
Generalized Estimating Equations 
Limitations 
• Relied on administrative data 
• Non-randomized study. Cannot control 
for unobserved differences in individuals 
using different treatments. 
• Other important outcomes were not 
included—abstinence, arrest, 
incarceration, death 
Conclusions 
• Most treatment episodes last less than 
2 years 
• Relapse rates are lower for MAT 
• Medicaid costs are lower for MAT 
• Relapses and costs decrease with 
longer treatment 
Policy implications 
• 6 month treatment limits would affect 
most MAT users 
• Limiting MAT is likely to increase 
relapse rates and costs  
• Current non-drug treatment does not 
appear to be a dependable alternative 
to MAT 
 
